SEELOS THERAPEUTICS INC(SEELQ.US)

Company Encyclopedia

SEELOS THERAPEUTICS INC

SEELQ.US

4.807 T

SEELQ.USMarket value -Rank by Market Cap -/-

Financial Score

11/01/2026 Update

PharmaceuticalsIndustry

Industry Ranking116/185

Industry medianC

Industry averageC

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreD
- ROE-10.86%D
- Profit Margin203.13%A
- Gross Margin-100.80%E
Growth ScoreA
- Revenue YoY76.05%A
- Net Profit YoY105.04%A
- Total Assets YoY-79.97%E
- Net Assets YoY40.37%A
Cash ScoreB
- Cash Flow Margin49.23%C
- OCF YoY76.05%A
Operating ScoreD
- Turnover0.28D
Debt ScoreE
- Gearing Ratio1281.56%E

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Weber Mark	3.41%	No Change	14/11/2024
Jane Street Group, LLC	2.81%	No Change	31/12/2024
Raj Mehra	0.11%	No Change	19/08/2024
Michael J. Golembiewski	0.05%	No Change	19/08/2024
Margaret R. Dalesandro	0%	No Change	19/08/2024
Richard W. Pascoe	0%	No Change	19/08/2024

News

Muna Therapeutics receives $1 million grant for Alzheimer's drug development, advancing Phase 1 trial of MNA-001.

Financial support has been secured for the continuation of the Phase 1 trial of MNA-001 and the validation of translational biomarkers related to TREM2 function in Alzheimer's disease. This funding will aid in conducting Phase 2 trials to evaluate the ability of MNA-001 to decelerate the progression of pathology and functional decline in patients. The validation of these translational biomarkers serves to validate Muna's distinctive approach in this research.

Unusual Whales·01/09/2026 02:07

Genomic Biomarkers Market to reach $50.31 billion by 2030, growing at a CAGR of 11.6% from $29.00 billion in 2025.

A recent report from MarketsandMarkets™ reveals that the Genomic Biomarkers Market is expected to witness significant growth, with projections indicating an increase from approximately USD 29.00 billion in 2025 to USD 50.31 billion by 2030. This growth reflects a Compound Annual Growth Rate (CAGR) of 11.6%. The report includes comprehensive market data, consisting of 708 tables and 56 figures distributed across 506 pages.

Unusual Whales·01/08/2026 23:34

Epistemic AI Analysis Reveals Strategic Business Decisions as the Leading Driver of Phase 3 Clinical Trial Terminations

A study by Epistemic AI published in Nature Reviews Drug Discovery reveals that strategic business decisions are the leading cause of Phase 3 clinical trial terminations, with rates doubling from 11% to 22% over the last decade. The research highlights a shift in pharmaceutical decision-making, where business factors like M&A activity now surpass clinical efficacy as reasons for trial failures. The study aims to inform decision-making to accelerate patient treatments and optimize drug development resources.

biopharmadive·01/08/2026 22:00

Psoriasis market to grow at 1.7% CAGR from 2025-2034 due to biologic innovations. Transition to high-efficacy treatments noted.

The market for psoriasis is steadily growing due to an increase in the number of people suffering from the disease, better detection rates, and increased patient availability of advanced treatments. There has been a notable transition from traditional systemic treatments to more effective biologics and targeted oral medications. This shift has led to a significant increase in revenue, with the market now valued at approximately [provide exact number if available].

Unusual Whales·01/08/2026 06:33

Surfing the AI wave: How pharma can harness agents in ERP

The rapid adoption of AI technology is transforming the pharmaceutical industry, enabling companies to streamline operations and enhance productivity. AI can alleviate repetitive tasks, allowing teams to focus on strategic initiatives. The journey of AI adoption unfolds in three phases: 1) Assistants that boost personal productivity, 2) Agents that automate structured processes, and 3) Autonomous processes that manage entire workflows. Successful implementation requires a focus on enriching employee experience, reinventing external engagement, reshaping business processes, and accelerating innovation. Companies must choose the right use cases to maximize AI's potential.

biopharmadive·01/08/2026 01:05